CTAC Patient Group Input Consultation: Glecaprevir Pibrentasvir
This hepatitis C medication is pan-genotypic and has been researched as an option for various patient populations including people living with HIV/HCV co-infection, people with past treatment failure, people living with cirrhosis and people who have had liver or renal transplants.
This informative webinar discussed the clinical trials supporting this new drug's examination by Canada's Common Drug Review.